MannKind Corporation Relocates Headquarters to Westlake Village
September 05 2017 - 9:00AM
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today the
company has fully relocated its corporate headquarters to a
12,596-square-foot location in the Westlake Landmark office park in
Westlake Village, California.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/1aeeebe3-558d-4ff0-910f-74247bf8c712
MannKind, which is currently commercializing Afrezza® (insulin
human) inhalation powder, moved from Valencia, California to be in
an area well known for its biopharmaceutical talent and to offer
greater convenience to its current employees.
“MannKind is a dynamic, fast-moving and rapidly growing company.
To fuel this growth, we need to add more talented people to our
team. Moving to Westlake Village, which is proximal to a large
number of companies in our industry, will help us attract top
talent,” said Michael Castagna, CEO, MannKind Corporation. ”We’re
excited to be a member of the Westlake Village and greater Conejo
Valley business community.”
MannKind has shattered the paradigm of diabetes management with
Afrezza, the only inhalable insulin that improves glycemic control
in adults with diabetes. MannKind also has additional therapeutic
products in the pipeline using its dry powder formulation as a drug
delivery platform.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the
development and commercialization of inhaled therapeutic products
for patients with diseases such as diabetes and pulmonary arterial
hypertension. MannKind is currently commercializing Afrezza®
(insulin human) inhalation powder, the Company’s first FDA approved
product, in the United States, where it is available by
prescription from pharmacies nationwide. MannKind is headquartered
in Westlake Village, California, and has a state-of-the art
manufacturing facility in Danbury, Connecticut. The Company also
employs field sales and medical representatives across the U.S. For
further information, visit www.mannkindcorp.com.
Company Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024